Dr Groenendijk goes through the main points of his talk the 3rd EurocanPlatform Translational Research Course, on resistance to targeted therapies in cancer. He emphasises the need for combination therapies over sequential therapies to maximise treatment effectiveness.
He explores the clinical significance this research could have, especially in terms of increasing overall survival in patients receiving targeted therapies. He gives examples of drug resistance, such as with vemurafenib in melanoma.
He then goes through the next steps this field will take, what obstacles they face and what the eventual benefit will be.